Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, Kelonia Join Hands to Develop In Vivo Cell Therapies
February 19, 2024
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
- SC Autoinjector Pen Versions of Metoject Approved in Japan: Eisai/Medac
February 16, 2024
- Evrysdi Filed for Pre-Symptomatic SMA in Japan: Chugai
February 16, 2024
- Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
- Ono Strikes New Oncology Pact with Numab
February 15, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
- CureApp’s Therapeutic App Makes Mark in PIII Alcohol Reduction Study
February 14, 2024
- Ono, Shattuck Ink Drug Discovery Collab on Bifunctional Fusion Proteins
February 14, 2024
- Takeda Earns US Nod for Oral EoE Drug after Resubmission
February 14, 2024
- Otsuka Cuts 2023 Profit Guidance after AD Agitation Trial Miss
February 14, 2024
- Otsuka’s AVP-786 Fails in PIII Alzheimer’s Agitation Study
February 14, 2024
- Manufacturing Change OK’ed for Januvia, Glactiv to Address Nitrosamine Impurities
February 13, 2024
- Chugai’s PNH Med Bags World’s 1st Approval in China
February 9, 2024
- Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…